nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—Neuropathy—Prednisolone—ankylosing spondylitis	0.00751	0.00751	CcSEcCtD
Deferoxamine—Aphasia—Methotrexate—ankylosing spondylitis	0.00749	0.00749	CcSEcCtD
Deferoxamine—Liver disorder—Methotrexate—ankylosing spondylitis	0.00713	0.00713	CcSEcCtD
Deferoxamine—Cataract—Dexamethasone—ankylosing spondylitis	0.00702	0.00702	CcSEcCtD
Deferoxamine—Cataract—Betamethasone—ankylosing spondylitis	0.00702	0.00702	CcSEcCtD
Deferoxamine—Neuropathy—Triamcinolone—ankylosing spondylitis	0.00691	0.00691	CcSEcCtD
Deferoxamine—Neuropathy—Methylprednisolone—ankylosing spondylitis	0.0069	0.0069	CcSEcCtD
Deferoxamine—Cyanosis—Methotrexate—ankylosing spondylitis	0.00687	0.00687	CcSEcCtD
Deferoxamine—Neuropathy—Betamethasone—ankylosing spondylitis	0.00627	0.00627	CcSEcCtD
Deferoxamine—Neuropathy—Dexamethasone—ankylosing spondylitis	0.00627	0.00627	CcSEcCtD
Deferoxamine—Visual disturbance—Prednisolone—ankylosing spondylitis	0.00613	0.00613	CcSEcCtD
Deferoxamine—Cataract—Prednisone—ankylosing spondylitis	0.00611	0.00611	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Prednisolone—ankylosing spondylitis	0.006	0.006	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Triamcinolone—ankylosing spondylitis	0.00552	0.00552	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Methylprednisolone—ankylosing spondylitis	0.00551	0.00551	CcSEcCtD
Deferoxamine—Neuropathy—Prednisone—ankylosing spondylitis	0.00546	0.00546	CcSEcCtD
Deferoxamine—Bone disorder—Methotrexate—ankylosing spondylitis	0.00538	0.00538	CcSEcCtD
Deferoxamine—Visual disturbance—Betamethasone—ankylosing spondylitis	0.00512	0.00512	CcSEcCtD
Deferoxamine—Visual disturbance—Dexamethasone—ankylosing spondylitis	0.00512	0.00512	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Dexamethasone—ankylosing spondylitis	0.00501	0.00501	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Betamethasone—ankylosing spondylitis	0.00501	0.00501	CcSEcCtD
Deferoxamine—Asthma—Triamcinolone—ankylosing spondylitis	0.00462	0.00462	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Prednisolone—ankylosing spondylitis	0.00439	0.00439	CcSEcCtD
Deferoxamine—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.00411	0.00411	CcSEcCtD
Deferoxamine—Infestation—Methylprednisolone—ankylosing spondylitis	0.00411	0.00411	CcSEcCtD
Deferoxamine—Bradycardia—Prednisolone—ankylosing spondylitis	0.00409	0.00409	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Triamcinolone—ankylosing spondylitis	0.00404	0.00404	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Methylprednisolone—ankylosing spondylitis	0.00403	0.00403	CcSEcCtD
Deferoxamine—Visual impairment—Prednisolone—ankylosing spondylitis	0.00387	0.00387	CcSEcCtD
Deferoxamine—Renal failure acute—Methotrexate—ankylosing spondylitis	0.00382	0.00382	CcSEcCtD
Deferoxamine—Bradycardia—Triamcinolone—ankylosing spondylitis	0.00376	0.00376	CcSEcCtD
Deferoxamine—Bradycardia—Methylprednisolone—ankylosing spondylitis	0.00375	0.00375	CcSEcCtD
Deferoxamine—Visual disturbance—Methotrexate—ankylosing spondylitis	0.00372	0.00372	CcSEcCtD
Deferoxamine—Hallucination—Methylprednisolone—ankylosing spondylitis	0.00367	0.00367	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Betamethasone—ankylosing spondylitis	0.00366	0.00366	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Dexamethasone—ankylosing spondylitis	0.00366	0.00366	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Methotrexate—ankylosing spondylitis	0.00365	0.00365	CcSEcCtD
Deferoxamine—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.00362	0.00362	CcSEcCtD
Deferoxamine—Arrhythmia—Prednisolone—ankylosing spondylitis	0.00359	0.00359	CcSEcCtD
Deferoxamine—Visual impairment—Methylprednisolone—ankylosing spondylitis	0.00355	0.00355	CcSEcCtD
Deferoxamine—Erythema—Prednisolone—ankylosing spondylitis	0.0035	0.0035	CcSEcCtD
Deferoxamine—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.00345	0.00345	CcSEcCtD
Deferoxamine—Bradycardia—Betamethasone—ankylosing spondylitis	0.00341	0.00341	CcSEcCtD
Deferoxamine—Bradycardia—Dexamethasone—ankylosing spondylitis	0.00341	0.00341	CcSEcCtD
Deferoxamine—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.00335	0.00335	CcSEcCtD
Deferoxamine—Hallucination—Dexamethasone—ankylosing spondylitis	0.00334	0.00334	CcSEcCtD
Deferoxamine—Hallucination—Betamethasone—ankylosing spondylitis	0.00334	0.00334	CcSEcCtD
Deferoxamine—Immune system disorder—Methylprednisolone—ankylosing spondylitis	0.00333	0.00333	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.00332	0.00332	CcSEcCtD
Deferoxamine—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.0033	0.0033	CcSEcCtD
Deferoxamine—Vision blurred—Prednisolone—ankylosing spondylitis	0.0033	0.0033	CcSEcCtD
Deferoxamine—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.00329	0.00329	CcSEcCtD
Deferoxamine—Visual impairment—Dexamethasone—ankylosing spondylitis	0.00323	0.00323	CcSEcCtD
Deferoxamine—Visual impairment—Betamethasone—ankylosing spondylitis	0.00323	0.00323	CcSEcCtD
Deferoxamine—Erythema—Triamcinolone—ankylosing spondylitis	0.00322	0.00322	CcSEcCtD
Deferoxamine—Erythema—Methylprednisolone—ankylosing spondylitis	0.00321	0.00321	CcSEcCtD
Deferoxamine—Angioedema—Prednisolone—ankylosing spondylitis	0.0032	0.0032	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Prednisone—ankylosing spondylitis	0.00319	0.00319	CcSEcCtD
Deferoxamine—Eye disorder—Betamethasone—ankylosing spondylitis	0.00313	0.00313	CcSEcCtD
Deferoxamine—Eye disorder—Dexamethasone—ankylosing spondylitis	0.00313	0.00313	CcSEcCtD
Deferoxamine—Asthma—Methotrexate—ankylosing spondylitis	0.00305	0.00305	CcSEcCtD
Deferoxamine—Angiopathy—Dexamethasone—ankylosing spondylitis	0.00304	0.00304	CcSEcCtD
Deferoxamine—Angiopathy—Betamethasone—ankylosing spondylitis	0.00304	0.00304	CcSEcCtD
Deferoxamine—Convulsion—Prednisolone—ankylosing spondylitis	0.00303	0.00303	CcSEcCtD
Deferoxamine—Eosinophilia—Methotrexate—ankylosing spondylitis	0.00302	0.00302	CcSEcCtD
Deferoxamine—Arrhythmia—Betamethasone—ankylosing spondylitis	0.003	0.003	CcSEcCtD
Deferoxamine—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.003	0.003	CcSEcCtD
Deferoxamine—Bradycardia—Prednisone—ankylosing spondylitis	0.00297	0.00297	CcSEcCtD
Deferoxamine—Angioedema—Triamcinolone—ankylosing spondylitis	0.00294	0.00294	CcSEcCtD
Deferoxamine—Angioedema—Methylprednisolone—ankylosing spondylitis	0.00293	0.00293	CcSEcCtD
Deferoxamine—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.00292	0.00292	CcSEcCtD
Deferoxamine—Erythema—Dexamethasone—ankylosing spondylitis	0.00292	0.00292	CcSEcCtD
Deferoxamine—Erythema—Betamethasone—ankylosing spondylitis	0.00292	0.00292	CcSEcCtD
Deferoxamine—Hallucination—Prednisone—ankylosing spondylitis	0.00291	0.00291	CcSEcCtD
Deferoxamine—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.00287	0.00287	CcSEcCtD
Deferoxamine—Oedema—Prednisolone—ankylosing spondylitis	0.00286	0.00286	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.00286	0.00286	CcSEcCtD
Deferoxamine—Dysuria—Methotrexate—ankylosing spondylitis	0.00285	0.00285	CcSEcCtD
Deferoxamine—Shock—Prednisolone—ankylosing spondylitis	0.00281	0.00281	CcSEcCtD
Deferoxamine—Convulsion—Triamcinolone—ankylosing spondylitis	0.00279	0.00279	CcSEcCtD
Deferoxamine—Tachycardia—Prednisolone—ankylosing spondylitis	0.00279	0.00279	CcSEcCtD
Deferoxamine—Convulsion—Methylprednisolone—ankylosing spondylitis	0.00278	0.00278	CcSEcCtD
Deferoxamine—Myalgia—Triamcinolone—ankylosing spondylitis	0.00274	0.00274	CcSEcCtD
Deferoxamine—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.00273	0.00273	CcSEcCtD
Deferoxamine—Myalgia—Methylprednisolone—ankylosing spondylitis	0.00273	0.00273	CcSEcCtD
Deferoxamine—Eye disorder—Prednisone—ankylosing spondylitis	0.00273	0.00273	CcSEcCtD
Deferoxamine—Infestation NOS—Methotrexate—ankylosing spondylitis	0.00272	0.00272	CcSEcCtD
Deferoxamine—Infestation—Methotrexate—ankylosing spondylitis	0.00272	0.00272	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.00271	0.00271	CcSEcCtD
Deferoxamine—Renal failure—Methotrexate—ankylosing spondylitis	0.00267	0.00267	CcSEcCtD
Deferoxamine—Angioedema—Betamethasone—ankylosing spondylitis	0.00267	0.00267	CcSEcCtD
Deferoxamine—Angioedema—Dexamethasone—ankylosing spondylitis	0.00267	0.00267	CcSEcCtD
Deferoxamine—Angiopathy—Prednisone—ankylosing spondylitis	0.00265	0.00265	CcSEcCtD
Deferoxamine—Immune system disorder—Prednisone—ankylosing spondylitis	0.00264	0.00264	CcSEcCtD
Deferoxamine—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.00263	0.00263	CcSEcCtD
Deferoxamine—Oedema—Triamcinolone—ankylosing spondylitis	0.00263	0.00263	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.00262	0.00262	CcSEcCtD
Deferoxamine—Arrhythmia—Prednisone—ankylosing spondylitis	0.00261	0.00261	CcSEcCtD
Deferoxamine—Infection—Triamcinolone—ankylosing spondylitis	0.00261	0.00261	CcSEcCtD
Deferoxamine—Infection—Methylprednisolone—ankylosing spondylitis	0.0026	0.0026	CcSEcCtD
Deferoxamine—Shock—Triamcinolone—ankylosing spondylitis	0.00258	0.00258	CcSEcCtD
Deferoxamine—Shock—Methylprednisolone—ankylosing spondylitis	0.00258	0.00258	CcSEcCtD
Deferoxamine—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.00257	0.00257	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisolone—ankylosing spondylitis	0.00256	0.00256	CcSEcCtD
Deferoxamine—Tachycardia—Triamcinolone—ankylosing spondylitis	0.00256	0.00256	CcSEcCtD
Deferoxamine—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.00256	0.00256	CcSEcCtD
Deferoxamine—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00254	0.00254	CcSEcCtD
Deferoxamine—Erythema—Prednisone—ankylosing spondylitis	0.00254	0.00254	CcSEcCtD
Deferoxamine—Convulsion—Dexamethasone—ankylosing spondylitis	0.00253	0.00253	CcSEcCtD
Deferoxamine—Convulsion—Betamethasone—ankylosing spondylitis	0.00253	0.00253	CcSEcCtD
Deferoxamine—Myalgia—Dexamethasone—ankylosing spondylitis	0.00249	0.00249	CcSEcCtD
Deferoxamine—Myalgia—Betamethasone—ankylosing spondylitis	0.00249	0.00249	CcSEcCtD
Deferoxamine—Hypotension—Methylprednisolone—ankylosing spondylitis	0.00245	0.00245	CcSEcCtD
Deferoxamine—Pain—Prednisolone—ankylosing spondylitis	0.00244	0.00244	CcSEcCtD
Deferoxamine—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.00241	0.00241	CcSEcCtD
Deferoxamine—Vision blurred—Prednisone—ankylosing spondylitis	0.0024	0.0024	CcSEcCtD
Deferoxamine—Urethral disorder—Methotrexate—ankylosing spondylitis	0.00239	0.00239	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.00239	0.00239	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.00239	0.00239	CcSEcCtD
Deferoxamine—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.00238	0.00238	CcSEcCtD
Deferoxamine—Oedema—Betamethasone—ankylosing spondylitis	0.00238	0.00238	CcSEcCtD
Deferoxamine—Oedema—Dexamethasone—ankylosing spondylitis	0.00238	0.00238	CcSEcCtD
Deferoxamine—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.00238	0.00238	CcSEcCtD
Deferoxamine—Infection—Betamethasone—ankylosing spondylitis	0.00237	0.00237	CcSEcCtD
Deferoxamine—Infection—Dexamethasone—ankylosing spondylitis	0.00237	0.00237	CcSEcCtD
Deferoxamine—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.00236	0.00236	CcSEcCtD
Deferoxamine—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Deferoxamine—Shock—Betamethasone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Deferoxamine—Shock—Dexamethasone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Deferoxamine—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Deferoxamine—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Deferoxamine—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Deferoxamine—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.00233	0.00233	CcSEcCtD
Deferoxamine—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.00233	0.00233	CcSEcCtD
Deferoxamine—Tachycardia—Dexamethasone—ankylosing spondylitis	0.00233	0.00233	CcSEcCtD
Deferoxamine—Tachycardia—Betamethasone—ankylosing spondylitis	0.00233	0.00233	CcSEcCtD
Deferoxamine—Angioedema—Prednisone—ankylosing spondylitis	0.00232	0.00232	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—ankylosing spondylitis	0.00228	0.00228	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—ankylosing spondylitis	0.00228	0.00228	CcSEcCtD
Deferoxamine—Urticaria—Prednisolone—ankylosing spondylitis	0.00227	0.00227	CcSEcCtD
Deferoxamine—Pain—Triamcinolone—ankylosing spondylitis	0.00225	0.00225	CcSEcCtD
Deferoxamine—Hypotension—Dexamethasone—ankylosing spondylitis	0.00223	0.00223	CcSEcCtD
Deferoxamine—Hypotension—Betamethasone—ankylosing spondylitis	0.00223	0.00223	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—ankylosing spondylitis	0.00221	0.00221	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—ankylosing spondylitis	0.0022	0.0022	CcSEcCtD
Deferoxamine—Convulsion—Prednisone—ankylosing spondylitis	0.0022	0.0022	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.0022	0.0022	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.00217	0.00217	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.00217	0.00217	CcSEcCtD
Deferoxamine—Arthralgia—Prednisone—ankylosing spondylitis	0.00216	0.00216	CcSEcCtD
Deferoxamine—Myalgia—Prednisone—ankylosing spondylitis	0.00216	0.00216	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.00215	0.00215	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.00214	0.00214	CcSEcCtD
Deferoxamine—Paraesthesia—Betamethasone—ankylosing spondylitis	0.00214	0.00214	CcSEcCtD
Deferoxamine—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.00214	0.00214	CcSEcCtD
Deferoxamine—Erythema—Methotrexate—ankylosing spondylitis	0.00212	0.00212	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.0021	0.0021	CcSEcCtD
Deferoxamine—Urticaria—Triamcinolone—ankylosing spondylitis	0.00209	0.00209	CcSEcCtD
Deferoxamine—Urticaria—Methylprednisolone—ankylosing spondylitis	0.00208	0.00208	CcSEcCtD
Deferoxamine—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.00208	0.00208	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.00208	0.00208	CcSEcCtD
Deferoxamine—Oedema—Prednisone—ankylosing spondylitis	0.00208	0.00208	CcSEcCtD
Deferoxamine—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.00207	0.00207	CcSEcCtD
Deferoxamine—Infection—Prednisone—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Deferoxamine—Shock—Prednisone—ankylosing spondylitis	0.00204	0.00204	CcSEcCtD
Deferoxamine—Pain—Betamethasone—ankylosing spondylitis	0.00204	0.00204	CcSEcCtD
Deferoxamine—Pain—Dexamethasone—ankylosing spondylitis	0.00204	0.00204	CcSEcCtD
Deferoxamine—Nervous system disorder—Prednisone—ankylosing spondylitis	0.00203	0.00203	CcSEcCtD
Deferoxamine—Tachycardia—Prednisone—ankylosing spondylitis	0.00203	0.00203	CcSEcCtD
Deferoxamine—Skin disorder—Prednisone—ankylosing spondylitis	0.00202	0.00202	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—ankylosing spondylitis	0.002	0.002	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.00195	0.00195	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.00195	0.00195	CcSEcCtD
Deferoxamine—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.00193	0.00193	CcSEcCtD
Deferoxamine—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00193	0.00193	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—ankylosing spondylitis	0.0019	0.0019	CcSEcCtD
Deferoxamine—Urticaria—Dexamethasone—ankylosing spondylitis	0.00189	0.00189	CcSEcCtD
Deferoxamine—Urticaria—Betamethasone—ankylosing spondylitis	0.00189	0.00189	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.00189	0.00189	CcSEcCtD
Deferoxamine—Dizziness—Prednisolone—ankylosing spondylitis	0.00189	0.00189	CcSEcCtD
Deferoxamine—Abdominal pain—Betamethasone—ankylosing spondylitis	0.00188	0.00188	CcSEcCtD
Deferoxamine—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.00188	0.00188	CcSEcCtD
Deferoxamine—Body temperature increased—Betamethasone—ankylosing spondylitis	0.00188	0.00188	CcSEcCtD
Deferoxamine—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.00188	0.00188	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisone—ankylosing spondylitis	0.00186	0.00186	CcSEcCtD
Deferoxamine—Pruritus—Triamcinolone—ankylosing spondylitis	0.00186	0.00186	CcSEcCtD
Deferoxamine—Pruritus—Methylprednisolone—ankylosing spondylitis	0.00185	0.00185	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—ankylosing spondylitis	0.00184	0.00184	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—ankylosing spondylitis	0.00181	0.00181	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—ankylosing spondylitis	0.00181	0.00181	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.0018	0.0018	CcSEcCtD
Deferoxamine—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.00179	0.00179	CcSEcCtD
Deferoxamine—Headache—Prednisolone—ankylosing spondylitis	0.00179	0.00179	CcSEcCtD
Deferoxamine—Dizziness—Triamcinolone—ankylosing spondylitis	0.00174	0.00174	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.00173	0.00173	CcSEcCtD
Deferoxamine—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00173	0.00173	CcSEcCtD
Deferoxamine—Infection—Methotrexate—ankylosing spondylitis	0.00172	0.00172	CcSEcCtD
Deferoxamine—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.0017	0.0017	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.0017	0.0017	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.0017	0.0017	CcSEcCtD
Deferoxamine—Nausea—Prednisolone—ankylosing spondylitis	0.0017	0.0017	CcSEcCtD
Deferoxamine—Pruritus—Dexamethasone—ankylosing spondylitis	0.00169	0.00169	CcSEcCtD
Deferoxamine—Pruritus—Betamethasone—ankylosing spondylitis	0.00169	0.00169	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—ankylosing spondylitis	0.00168	0.00168	CcSEcCtD
Deferoxamine—Vomiting—Triamcinolone—ankylosing spondylitis	0.00167	0.00167	CcSEcCtD
Deferoxamine—Vomiting—Methylprednisolone—ankylosing spondylitis	0.00167	0.00167	CcSEcCtD
Deferoxamine—Urticaria—Prednisone—ankylosing spondylitis	0.00165	0.00165	CcSEcCtD
Deferoxamine—Headache—Triamcinolone—ankylosing spondylitis	0.00165	0.00165	CcSEcCtD
Deferoxamine—Headache—Methylprednisolone—ankylosing spondylitis	0.00164	0.00164	CcSEcCtD
Deferoxamine—Body temperature increased—Prednisone—ankylosing spondylitis	0.00164	0.00164	CcSEcCtD
Deferoxamine—Abdominal pain—Prednisone—ankylosing spondylitis	0.00164	0.00164	CcSEcCtD
Deferoxamine—Diarrhoea—Betamethasone—ankylosing spondylitis	0.00163	0.00163	CcSEcCtD
Deferoxamine—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.00163	0.00163	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—ankylosing spondylitis	0.00162	0.00162	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.00158	0.00158	CcSEcCtD
Deferoxamine—Dizziness—Betamethasone—ankylosing spondylitis	0.00158	0.00158	CcSEcCtD
Deferoxamine—Dizziness—Dexamethasone—ankylosing spondylitis	0.00158	0.00158	CcSEcCtD
Deferoxamine—Nausea—Triamcinolone—ankylosing spondylitis	0.00156	0.00156	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—ankylosing spondylitis	0.00156	0.00156	CcSEcCtD
Deferoxamine—Nausea—Methylprednisolone—ankylosing spondylitis	0.00156	0.00156	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—ankylosing spondylitis	0.00155	0.00155	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisone—ankylosing spondylitis	0.00153	0.00153	CcSEcCtD
Deferoxamine—Vomiting—Betamethasone—ankylosing spondylitis	0.00151	0.00151	CcSEcCtD
Deferoxamine—Vomiting—Dexamethasone—ankylosing spondylitis	0.00151	0.00151	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.0015	0.0015	CcSEcCtD
Deferoxamine—Headache—Dexamethasone—ankylosing spondylitis	0.00149	0.00149	CcSEcCtD
Deferoxamine—Headache—Betamethasone—ankylosing spondylitis	0.00149	0.00149	CcSEcCtD
Deferoxamine—Pain—Methotrexate—ankylosing spondylitis	0.00148	0.00148	CcSEcCtD
Deferoxamine—Pruritus—Prednisone—ankylosing spondylitis	0.00147	0.00147	CcSEcCtD
Deferoxamine—Diarrhoea—Prednisone—ankylosing spondylitis	0.00142	0.00142	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.00142	0.00142	CcSEcCtD
Deferoxamine—Nausea—Dexamethasone—ankylosing spondylitis	0.00142	0.00142	CcSEcCtD
Deferoxamine—Nausea—Betamethasone—ankylosing spondylitis	0.00142	0.00142	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—ankylosing spondylitis	0.00138	0.00138	CcSEcCtD
Deferoxamine—Dizziness—Prednisone—ankylosing spondylitis	0.00137	0.00137	CcSEcCtD
Deferoxamine—Abdominal pain—Methotrexate—ankylosing spondylitis	0.00137	0.00137	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—ankylosing spondylitis	0.00137	0.00137	CcSEcCtD
Deferoxamine—Vomiting—Prednisone—ankylosing spondylitis	0.00132	0.00132	CcSEcCtD
Deferoxamine—Headache—Prednisone—ankylosing spondylitis	0.0013	0.0013	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.00128	0.00128	CcSEcCtD
Deferoxamine—Nausea—Prednisone—ankylosing spondylitis	0.00123	0.00123	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—ankylosing spondylitis	0.00123	0.00123	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—ankylosing spondylitis	0.00119	0.00119	CcSEcCtD
Deferoxamine—Dizziness—Methotrexate—ankylosing spondylitis	0.00115	0.00115	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—ankylosing spondylitis	0.0011	0.0011	CcSEcCtD
Deferoxamine—Headache—Methotrexate—ankylosing spondylitis	0.00109	0.00109	CcSEcCtD
Deferoxamine—Nausea—Methotrexate—ankylosing spondylitis	0.00103	0.00103	CcSEcCtD
